We report the activities of a number of thiazolides [2-hydroxyaroyl-N-(thiazol-2-yl) amides] against hepatitis C virus (HCV) genotypes IA and IB, using replicon assays. The structure– activity relationships (SARs) of thiazolides against HCV are less predictable than against hepatitis B virus (HBV), though an electron-withdrawing group at C (5′) generally correlates with potency. Among the related salicyloylanilides, the m-fluorophenyl ...